Avril N - Search Results

1

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T. Kayani I, et al. Among authors: avril n. Clin Cancer Res. 2011 Sep 15;17(18):6021-8. doi: 10.1158/1078-0432.CCR-10-3309. Epub 2011 Jul 8. Clin Cancer Res. 2011. PMID: 21742806 Clinical Trial.

2

The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.

Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A. Avril N, et al. Int J Urol. 2010 Jun;17(6):501-11. doi: 10.1111/j.1442-2042.2010.02509.x. Epub 2010 Apr 1. Int J Urol. 2010. PMID: 20370848 Review.

3

The role of FDG-PET/CT in gynaecological cancers.

Rockall AG, Cross S, Flanagan S, Moore E, Avril N. Rockall AG, et al. Among authors: avril n. Cancer Imaging. 2012 Mar 5;12(1):49-65. doi: 10.1102/1470-7330.2012.0007. Cancer Imaging. 2012. PMID: 22391444 Free PMC article. Review.

4

New ways of assessing ovarian cancer response: metabolic imaging and beyond.

Rockall A, Munari A, Avril N. Rockall A, et al. Among authors: avril n. Cancer Imaging. 2012 Sep 28;12(2):310-4. doi: 10.1102/1470-7330.2012.9004. Cancer Imaging. 2012. PMID: 23022953 Free PMC article. Review.

5

Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume.

Rockall AG, Avril N, Lam R, Iannone R, Mozley PD, Parkinson C, Bergstrom D, Sala E, Sarker SJ, McNeish IA, Brenton JD. Rockall AG, et al. Among authors: avril n. Clin Cancer Res. 2014 May 15;20(10):2751-60. doi: 10.1158/1078-0432.CCR-13-2634. Epub 2014 Feb 26. Clin Cancer Res. 2014. PMID: 24573555 Free PMC article.

6

123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.

Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, Avril N, Monson JP, Grossman AB, Reznek RH. Bhatia KS, et al. Among authors: avril n. Clin Endocrinol (Oxf). 2008 Aug;69(2):181-8. doi: 10.1111/j.1365-2265.2008.03256.x. Epub 2008 Apr 3. Clin Endocrinol (Oxf). 2008. PMID: 18394016

7

Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR. Coward J, et al. Among authors: avril n. Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27. Clin Cancer Res. 2011. PMID: 21795409 Free PMC article. Clinical Trial.

8

FDG-PET/CT as a molecular biomarker in ovarian cancer.

Nowosinska E, Avril S, Murray I, Szyszko T, Avril N. Nowosinska E, et al. Among authors: avril s, avril n. Cancer Biomark. 2010-2011;8(4-5):167-75. doi: 10.3233/CBM-2011-0219. Cancer Biomark. 2010. PMID: 22045351 Review.

9

Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W. Avril N, et al. J Clin Oncol. 2005 Oct 20;23(30):7445-53. doi: 10.1200/JCO.2005.06.965. Epub 2005 Sep 12. J Clin Oncol. 2005. PMID: 16157939

10

Response to therapy in breast cancer.

Avril N, Sassen S, Roylance R. Avril N, et al. J Nucl Med. 2009 May;50 Suppl 1:55S-63S. doi: 10.2967/jnumed.108.057240. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380410 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

121 results

Search Page